Call 800 665 0411 to learn about our services for your stock

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS

Share on StockTwits

Stock of Canadian Health Tech Firm Upgraded To Good

Source: Sadif Research


June 2, 2023 ( Newswire) Since the previous rating, this firm has experienced improvements in its business market sentiment and technicals, noted a SADIF Investment Analytics report.

Reliq Health Technologies Inc. (RHT:TSX.V; RQHTF:OTCQB; A2AJTB:WKN) had its stock upgraded to Good from Above Average by Sadif Investment Analytics, the research firm reported in a rating update note.

The Canadian health technology company "has a bright prospect with an overall score of 87/100" (100 being the highest), Sadif wrote. "Overall, we expect Reliq to be a good long-term investment that is likely to deliver long-term returns."

The total score reflects how Reliq fared since its last rating in a dozen categories, as determined using the Summary StockMarks rating system, versus the entire population of 2,193 Canada-listed companies rated today. The current scores are based on data as of the market close on May 24, 2023.

Reasons for the Uprating

Sadif ascribed the improved overall performance and, thus, upgraded the rating to improvements in Reliq's business market sentiment and in its technicals (79%). Current investor sentiment toward the healthcare technology firm is "bullish and with a positive outlook," Sadif described. Analyst consensus about Reliq is positive, too.

Also working in Reliq's favor are fair financials, good earnings quality, low information risk, and acceptable market risk. Operational risk is average.

When compared to its closest competitor, Playmaker Capital Inc. (PMKR:TSX.V; PMKRF:OTCQX), Reliq shows greater undervaluation and is equally likely to outperform the market.

More Info: Newswire

This news is published on the Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire

Global investors must adhere to regulations of each country. Please read privacy policy:

That's all it takes to get an article published on Investor Ideas - Learn More - A Leading Global Investor Website for Biotech Industry Stocks - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

Buy a biotech guest post on